Analyst Price Targets — BIOA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 31, 2026 6:36 pm | Adam Walsh | Roth Capital | $25.00 | $9.04 | TheFly | BioAge Labs price target lowered to $25 from $36 at Roth Capital |
| July 31, 2026 5:29 pm | — | Jefferies | $21.00 | $9.40 | TheFly | BioAge Labs price target lowered at Jefferies after Novo trial miss |
| May 27, 2026 8:18 am | Adam Walsh | Roth Capital | $36.00 | $16.20 | TheFly | BioAge Labs initiated with a Buy at Roth Capital |
| May 13, 2026 9:54 am | — | BTIG | $40.00 | $18.19 | TheFly | BioAge Labs initiated with a Buy at BTIG |
| March 27, 2026 10:21 am | — | Needham | $50.00 | $16.15 | TheFly | BioAge Labs initiated with a Buy at Needham |
| February 18, 2026 11:08 am | Roger Song | Jefferies | $62.00 | $19.63 | TheFly | BioAge Labs upgraded to Buy from Hold at Jefferies |
| February 4, 2026 1:30 pm | — | Morgan Stanley | $23.00 | $19.99 | TheFly | BioAge Labs price target raised to $23 from $12 at Morgan Stanley |
| December 5, 2025 6:29 pm | — | Morgan Stanley | $12.00 | $11.40 | TheFly | BioAge Labs upgraded to Equal Weight from Underweight at Morgan Stanley |
| March 7, 2025 1:24 pm | — | Morgan Stanley | $5.00 | $4.55 | TheFly | BioAge Labs assumed with an Underweight at Morgan Stanley |
| December 9, 2024 8:00 am | Roger Song | Jefferies | $7.00 | $4.65 | StreetInsider | Jefferies Downgrades BioAge Labs Inc (BIOA) to Hold |
Latest News for BIOA
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ: BIOA) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 214,546 shares of the company's stock, valued at approximately $3,746,000. Dimensional Fund Advisors LP owned 0.48% of
BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.6 per share a year ago.
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026
BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting therapies.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BIOA.
U.S. House Trading
No House trades found for BIOA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.